Sodium nitroprusside–enhanced cardiopulmonary resuscitation has shown superior resuscitation rates and neurologic outcomes in large animal models supporting the need for a randomized human clinical trial. This study is the first to show nonselective pulmonary vasodilation as a potential mechanism for the hemodynamic benefits. The pulmonary shunting that is created requires increased oxygen treatment, but the overall improvement in blood flow increases minute oxygen delivery to tissues. In this context, hypoxemia is an important safety endpoint and a 100% oxygen ventilation strategy may be necessary for the first human clinical trial.
Bibliographical noteFunding Information:
This study was funded by an R01 research grant (R01HL108926) from the National Institutes of Health National Heart, Lung, and Blood Institute to Dr. Yannopoulos. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
© 2020 The Authors
- cardiopulmonary resuscitation
- coronary perfusion pressure
- lactic acid
- pulmonary vasodilation
- sodium nitroprusside